Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations are in order for postdoctoral research scientist Dr Christoph Treiber who has been awarded a Starting Grant from the European Research Council. His funded project will investigate the genetic components that may contribute to diversity of brain function and behaviour.

15 fruit fly brains in a colourful grid design © Gil Costa (www.gilcosta.com)

A large part of our genome is made up of potentially mobile pieces called transposons, also known as ‘jumping genes’ for their ability to change their position. While humans largely share the same genes in our DNA, the combination of transposons are unique for each person. Recent evidence uncovered in 2020 by Dr Christoph Treiber and Professor Scott Waddell in the Centre for Neural Circuits and Behaviour (CNCB) suggests that transposons are particularly active in the brain. This has given rise to a new hypothesis that transposons might change brain functions and contribute to the diversity of behaviours across individuals within a population.

Dr Christoph Treiber of the Waddell group has now been awarded a European Research Council (ERC) Starting Grant to begin an independent line of research to interrogate this hypothesis over the next five years. The award of more than £1.25 million will “help us understand whether our unique transposon fingerprint contributes to who we are. Transposons could be a key component of our personality.” (Dr Christoph Treiber).

With this new award, Dr Treiber will combine two novel and ground-breaking techniques to test the hypothesis in the fruit fly brain, a well-established model for studying how genes alter behaviours. The first, single-cell transcriptomics, has been pioneered by Dr Treiber and Dr Vincent Croset in the Waddell Group at the CNCB. The second, PacBio® single-molecule real-time (SMRT) sequencing generates full length cDNA sequences from cells and tissues.

Read the full story on the DPAG website. 

Similar stories

Attention and memory deficits persist for months after recovery from mild Covid

Researchers from Oxford’s Department of Experimental Psychology and Nuffield Department of Clinical Neurosciences have shown that people who have had Covid but don’t complain of long Covid symptoms in daily life nevertheless can show degraded attention and memory for up to 6-9 months.

New book expands the horizons of brain research

A pioneering book from Professor Zoltán Molnár and Yale Professors Tamas Horvath and Joy Hirsch to be released on 1 February 2022 addresses the fundamental relationship between the body, brain and behaviour.

New research sheds light on how ultrasound could be used to treat psychiatric disorders

A new study in macaque monkeys has shed light on which parts of the brain support credit assignment processes (how the brain links outcomes with its decisions) and, for the first time, how low-intensity transcranial ultrasound stimulation (TUS) can modulate both brain activity and behaviours related to these decision-making and learning processes.

Dramatic fall in hospital admissions for child infections since start of Covid-19 pandemic

Since the onset of the Covid-19 pandemic, there have been dramatic reductions in hospital admissions for common and severe childhood infections in England, most likely due to social distancing measures, school and workplace closures, and travel restrictions, finds a study published by The BMJ today.

Rosalind Franklin Institute and Pharmacology announce strategic partnership in Next Generation Chemistry

The Rosalind Franklin Institute and the University of Oxford’s Department of Pharmacology have entered into a strategic partnership for Next Generation Chemistry.

New blood-based test is the first ever to simultaneously identify if a patient has cancer and if it has spread

A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms. The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.